Table 1. Characteristics of Studies Included in the Meta-analysis.

Study	Quality (Scores)	Therapy	n	Age Median	Male (%)	Stage IIIB(%)	Stage IV(%)	Non-squ (%)	OS Median	PFS Median
Scagliotti et al. [7]	3	PEM- 500 mg/m2 d1+P-75 mg/m2 d1, q3w	862	61.1	70.2	23.8	76.2	71.7	10.3	4.8
		GEM-1,250 mg/m2 d1,8+P-75 mg/m2 d1, q3w	863	61.0	70.1	24.3	75.7	73.5	10.3	5.1
Gronberg et al. [9]	3	PEM- 500 mg/m2 d1+P#-AUC 5 d1, q3w	219	64	56	29	71	74	7.3	NA
		GEM-1,000 mg/m2 d1,8+P#-AUC 5 d1, q3w	217	66	59	28	72	77	7.0	NA
Socinski et al. [10]	2	PEM- 500 mg/m2 d1+P#-AUC 6 d1, q3w	74	66	55	7	93	70	12.7	NA
		Doc-75 mg/m2 d1+P#-AUC 6 d1, q3w	72	65	58	8	92	81	9.2	NA
Rodrigues-Pereira et al. [17]	3	PEM- 500 mg/m2 d1+P#-AUC 5 d1, q3w	106	60.1	60.4	16	84	100	14.9	5.8
		Doc-75 mg/m2 d1+P#-AUC 5 d1, q3w	105	58.9	47.6	21.9	78.1	100	14.7	6.0

Abbreviations: PEM, pemetrexed; GEM, gemcitabine; Doc, docetaxel; P, cisplatin; P#, carboplatin; Ade, adenocarcinoma; Non-squ, non-squamous cell carcinoma; AUC, area under the concentration/time curve. NA, not available; OS, overall survival; progression-free survival.